As an ATP noncompetitive selective inhibitor of MEK1/2, PD-0325901 displays significant antitumor effects in melanoma, head and neck, and BRAF-mutated papillary thyroid cancer (75, 76). This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.